Loading
Life sciences · Journal article
Scientific Reports · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract This study proposes a new molecular concept for the treatment of obesity and diabetes, using peptide-fatty acid complexes. Oral administration of the BAMLET complex reduced weight gain and hyperglycemia, in C57BL/6 mice with diet induced obesity. Intestinal glucose and lipid metabolism was broadly affected, including FGF19- and adiponectin-controlled gene networks. BAMLET treatment further targeted the glucose transporter GLUT2, reducing intestinal Slc2a2 expression and GLUT2 protein levels and targeting its glucose-binding pocket. Lowered GLUT2 levels and inhibition of glucose uptake in cellular models supported a potential in vivo effect on glucose uptake. BAMLET treatment further inhibited weight gain, adiponectin and leptin associated gene networks in chronically obese B6.Cg- Lep ob /J mice and visceral and systemic adipose tissue growth was reduced in both backgrounds. Interactions with the oleic acid binding pocket of the AdipoR2 adiponectin receptor and the Ig-like domain of the leptin receptor were predicted in silico and confirmed by surface plasmon resonance. Relevance for chronic diabetes was further suggested by rapid effects of BAMLET in C57BL/6- Ins2 Akita /J mice, with reversal of intestinal leakiness after three days and weight gain with continued treatment. The results identify BAMLET an orally available metabolic regulator and suggest a new, non-toxic approach to treating metabolic disorders.